The Unopened Envelope: What UK Shareholders Surrender by Letting a Rights Issue Lapse
Photo: UK shareholder reviewing rights issue documents and financial statements at a desk, via www.shutterstock.com
Rights issues tend to return to the UK market when boards need to repair balance sheets, fund acquisitions or reassure lenders. For large institutions, the process is routine. For retail shareholders, it often arrives as an envelope, a portal notification and a deadline that falls in the middle of an already busy month. The temptation to do nothing is understandable. It is also one of the more expensive habits available to a UK equity investor.
A rights issue is a pre-emptive offer: existing holders are given the right to buy new shares, usually at a discount to the prevailing market price, in proportion to their existing holding. The decision is not simply whether to put more money into the company. It is whether to protect, monetise or surrender an asset that has been created alongside the existing shares. Refusing the offer can be rational. Letting the entitlement lapse by accident rarely is.
What the nil-paid entitlement actually represents
When a UK company announces a rights issue, it sets a record date. Holders on the register at that point receive a provisional allotment of rights. Those rights are typically renounceable, meaning they can be sold before the take-up deadline. In CREST and through most UK brokers, the entitlement appears as a separate nil-paid line. The name is useful: the investor has not yet paid the subscription price, but the entitlement already has an economic value because it carries the right to buy new shares at a fixed, often discounted, price.
That value is not imaginary. If the rights are tradable, the nil-paid line can be sold in the market during the dealing window. If the holder does nothing and the issue is not fully taken up, the company may sell lapsed entitlements and pass on the net proceeds, subject to thresholds and costs. But that backstop should not be confused with a guaranteed outcome. In practice, lapsed entitlements can be sold at an uncertain price, after expenses, or may be treated as forfeited if the proceeds are below the company's de minimis limit. The result is that an investor who ignores the paperwork may receive nothing at all.
The dilution arithmetic, plainly
Dilution sounds abstract until it is applied to a holding. Suppose a UK company has 100 million shares trading at 200p. It announces a 1-for-4 rights issue at 140p. The theoretical ex-rights price, or TERP, is calculated by blending the existing shares with the new money: four shares at 200p plus one new share at 140p gives 940p across five shares, or 188p each. The nil-paid entitlement is therefore worth roughly 48p per right: the 188p theoretical ex-rights price less the 140p subscription price.
A holder with 1,000 shares is offered 250 new shares. Taking up the offer requires £350. After the issue, the investor owns 1,250 shares at a theoretical 188p, worth £2,350. Before the issue, the holding was worth £2,000. The extra £350 has simply been converted into shares, and the theoretical value is preserved.
If the same investor refuses but sells the 250 nil-paid rights at about 48p, the proceeds are £120. The existing 1,000 shares are then worth about £1,880 at the theoretical ex-rights price, giving £2,000 in total. Economically, the investor has sold part of the stake and kept the rest. If the investor does nothing and the rights lapse worthless, the existing shares are still worth £1,880, but the £120 entitlement has gone. That is the accidental loss: full dilution without compensation.
When taking the cash beats following the shares
Following rights is not automatically the right answer. A rights issue asks existing holders to increase their exposure to the same company, often when the company's prospects have changed. An investor who would not buy more shares in the open market at the subscription price should ask why they are willing to do so through a rights issue. The discount is a feature of the mechanics, not a reason in itself to commit fresh capital.
Selling the nil-paid entitlement is the cleaner refusal. It converts the right into cash and allows the investor to retain the existing holding at the diluted size they have chosen. For a small holding, dealing charges and the broker's handling of nil-paid lines matter. Some UK platforms support nil-paid trading directly; others require instructions by phone or through a corporate actions team. The costs can be material relative to a modest entitlement, but they are usually preferable to forfeiture.
There is also a portfolio-level argument. If a holding has grown too large, a rights issue presents an opportunity to rebalance without selling the ordinary shares. Taking the cash from the nil-paid line reduces the investor's commitment while keeping the remaining position intact. For income-focused holders, the decision should be weighed against the company's dividend prospects and balance-sheet risk, not simply the headline discount.
Deadline mechanics and the mistakes that cost money
The timetable is the practical trap. The ex-rights date, record date, provisional allotment letter, nil-paid dealing period and take-up deadline are distinct events. A shareholder who buys after the ex-rights date does not receive the rights. A shareholder who sells the existing shares before the record date may sell the entitlement with them. A shareholder who waits for a paper letter may find that the broker's online deadline is earlier than the registrar's final cut-off.
Common errors follow from those mechanics. The first is assuming that doing nothing preserves the status quo. It does not: refusal without selling the nil-paid entitlement accepts dilution and gives up the compensation. The second is missing the broker's cut-off because the letter went to an old address. The third is selling the ordinary shares but forgetting to deal with the separate nil-paid line. The fourth is overlooking fractional entitlements, which may be aggregated and sold for the investor's benefit but can also be rounded down. The fifth is treating the subscription price as a bargain without checking the TERP and the company's reason for raising money.
Rights issues are corporate actions, not junk mail. For UK shareholders, the disciplined approach is to open the envelope, identify the deadline, calculate the entitlement's value and make an active choice: take up the shares, sell the nil-paid rights, or accept dilution with eyes open. Refusing the cash is a legitimate decision. Refusing to decide is not.
